Cytek Biosciences Balances Growth With Margin Strain

Cytek Biosciences, Inc. ((CTKB)) has held its Q4 earnings call. Read on for the main highlights of the call.

Cytek Biosciences’ latest earnings call painted a mixed picture, combining record quarterly revenue and accelerating demand with mounting margin and profitability pressures. Management struck a tone of cautious optimism, pointing to a clear second‑half recovery and strong recurring revenue, while acknowledging that tax‑driven GAAP losses, higher costs and manufacturing headwinds will weigh on results in the near term.

Record Q4 Revenue and Re‑Acceleration

Cytek delivered its strongest quarter ever, posting fourth quarter 2025 revenue of $62.1 million, up 8% year over year and marking the highest revenue in the company’s history. The quarter capped a clear sequential recovery across 2025, as revenue trends improved from an 8% decline in Q1 to growth of 2% in Q3 and 8% in Q4.

Full‑Year Return to Growth in Second Half

For 2025, Cytek generated $201.5 million in revenue, up 1% from 2024, with growth driven almost entirely by a stronger second half. Revenue in the back half of 2025 was about 5% higher than the second half of 2024, underscoring a pivot from a weak first half to a more resilient demand environment later in the year.

Installed Base Expansion and Unit Volume Growth

The company continued to expand its footprint, adding 208 instruments in Q4 to end 2025 with an installed base of 3,664 units. Unit volumes grew 22% for the full year and accelerated to 26% growth in the fourth quarter, highlighting strong adoption even as headline revenue growth remained modest.

New Products and Industry Recognition

Cytek’s innovation engine contributed meaningfully, with the Aurora Evo launched in May 2025 helping drive 21% unit growth in the combined Aurora category in Q4 versus the prior year. The company also gained external validation as its Muse Micro System won a 2025 Biotech Breakthrough Award for drug discovery solutions, reinforcing its positioning in high‑end research workflows.

Recurring Revenue and Service Strength

Recurring revenue continued to scale, representing 34% of total revenue in 2025 and growing 21% year over year, providing a more stable base for the business. Service revenue was a standout, rising 25% in Q4 and about 21% for the year, supported by the expanding installed base and higher instrument utilization.

Reagent and Application Momentum

Reagents remained a high‑growth category, with revenue advancing more than 20% in Q4 across all regions except the U.S., and exceeding 25% growth for the full year. Management credited faster delivery, an expanded catalog and more focused sales efforts, signaling that reagents are becoming an increasingly important driver of recurring revenue.

Digital and Bioinformatics Adoption

Cytek’s digital ecosystem gained traction, as Cytek Cloud users climbed to more than 24,000 by the end of 2025, an increase of over 50% year over year. That equates to nearly eight users per installed full spectrum profiling instrument and supports higher attachment of reagents and services as customers deepen their engagement with the platform.

Operational Actions and Balance Sheet Position

Operationally, the company’s new Singapore manufacturing facility began generating revenue in under 100 days, advancing its regional manufacturing strategy and long‑term cost initiatives. Cytek ended 2025 with $261.5 million in cash, cash equivalents and marketable securities and repurchased $15.1 million of stock, giving it financial flexibility despite earnings volatility.

Margin Compression Across 2025

Despite top‑line progress, profitability came under pressure, with GAAP gross margin falling to 53% in Q4 from 59% a year earlier and adjusted gross margin slipping to 55% from 61%. For the full year, GAAP gross margin declined to 52% from 55% and adjusted gross margin to 55% from 59%, reflecting a tougher cost environment.

GAAP Net Loss Inflated by Tax Allowance

Reported losses swelled, as Cytek posted a Q4 2025 GAAP net loss of $44.1 million, including a $38.1 million valuation allowance against deferred tax assets. For the full year, GAAP net loss reached $66.5 million and included a $33.1 million valuation allowance, non‑cash accounting items that materially amplified stated losses without affecting cash.

Operating Expenses and Profitability Pressure

Operating expenses increased notably, with Q4 2025 opex rising 25% year over year to $38.5 million, or by about $5.2 million when adjusting for a prior‑year one‑time reduction. Full year operating expenses moved up to $144.8 million from $131.6 million, driven in part by higher general and administrative spending, including legal and related costs.

Declines in Adjusted Profitability Metrics

Adjusted profitability weakened as well, with adjusted EBITDA dropping to $4.5 million in Q4 2025 from $12.5 million a year earlier, or from $9.9 million excluding a nonrecurring benefit. For the full year, adjusted EBITDA slid to $5.0 million from $22.4 million, and adjusted EBITDA excluding investment income turned negative $3.1 million, underscoring the pressure on core operating performance.

Product Margins and Manufacturing Headwinds

Product gross margins were squeezed by higher material costs, tariffs and elevated overhead tied to the transition of production overseas, including duplicate costs during the ramp. These dynamics weighed on both quarterly and full‑year product margins, though management framed the manufacturing shift as a strategic move designed to benefit margins over the longer term.

Biopharma and Pharma Instrument Weakness

Not all end markets were strong, as revenue from biotech, pharma and contract research customers declined in the fourth quarter, with biopharma revenue down 6% year over year. U.S. instrument sales to biotech and pharma softened after a strong third quarter, highlighting ongoing choppiness in life‑science capital spending.

Early‑Year Demand Weakness and Volatility

The year began on a soft note, with Q1 2025 revenue down 8% year over year and first‑half revenue off nearly 5%, which management linked to public policy effects and broader uncertainty in life‑science budgets. The recovery that emerged in the second half underscores the volatility of demand, but also suggests that some customers resumed investment as the year progressed.

Legal and One‑Time Costs Cloud Comparisons

General and administrative expenses were inflated by patent‑related legal spending, adding noise to year‑over‑year comparisons and compressing margins. Additional one‑time items, including costs tied to an at‑the‑market offering, further complicated the expense profile and contributed to volatility in reported operating results.

Guidance and Forward‑Looking Outlook

For 2026, Cytek guided to constant‑currency revenue of $205 million to $212 million, implying modest 2% to 5% growth from 2025 and assuming no major benefit from tariff changes. Management expects to maintain positive adjusted EBITDA while leaning on strong instrument demand in Asia‑Pacific, rebounds in the U.S. and Europe, and continued rapid growth in recurring revenue, services and reagents, building off Q4 momentum and a growing installed base and cloud user community.

Cytek’s earnings call showcased a company pushing forward on commercial and operational fronts, but grappling with cost inflation, tax charges and market volatility that are dampening near‑term profitability. For investors, the story hinges on whether the strengthening second‑half trends, recurring revenue expansion and manufacturing shifts can translate into more durable growth and margin recovery over the next few years.